Bayer filed a lawsuit accusing a rival, Johnson & Johnson, of launching a “false advertising campaign” based on flawed data ...
The FDA expects a flood of applications for a new "plausible mechanism pathway" for approval of bespoke gene-editing treatments.
The AI ‘modernization’ project at CMS. In the not-too-distant future, the entire process of finding Medicare coverage may be ...
The No. 2 official at the CDC has resigned, adding to the drama and chaos surrounding the agency's leadership.
We’ve got some big acquisition news today, and also some politics — specifically a look at how pharma lobbyists, who have ...
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Pharmaceutical companies are boosting their spending on lobbying firms with connections to the White House ...
Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial.
Business is booming for Trump-connected lobbying firms as pharma giants see new opportunity to influence the FDA.
Lawmakers will likely have a lot to say about health care this year. Paradoxically, they probably won't accomplish much on ...
A provocative new proposal has offered the FDA a way to let a broad swath of potentially risky AI devices flood the market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results